Aerobic Exercise Training Prevents Heart Failure-Induced
Skeletal Muscle Atrophy by Anti-Catabolic, but Not
Anabolic Actions by Souza, Rodrigo W.A. et al.
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
Nutrition and Health Sciences -- Faculty 
Publications Nutrition and Health Sciences, Department of 
10-17-2014 
Aerobic Exercise Training Prevents Heart Failure-Induced Skeletal 
Muscle Atrophy by Anti-Catabolic, but Not Anabolic Actions 
Rodrigo W.A. Souza 
Sao Paulo State University 
Warlen P. Piedade 
Sao Paulo State University 
Luana C. Soares 
Sao Paulo State University 
Paula A. T. Souza 
Sao Paulo State University 
Andreo F. Aguiar 
North University of Parana 
See next page for additional authors Follow this and additional works at: https://digitalcommons.unl.edu/nutritionfacpub 
 Part of the Human and Clinical Nutrition Commons, Molecular, Genetic, and Biochemical Nutrition 
Commons, and the Other Nutrition Commons 
Souza, Rodrigo W.A.; Piedade, Warlen P.; Soares, Luana C.; Souza, Paula A. T.; Aguiar, Andreo F.; Vechetti, 
Ivan Jose Jr; Campos, Dijon H.S.; Fernandes, Ana A. H.; Okoshi, Katashi; Carvalho, Robson F.; Cicogna, 
Antonio C.; and Dal-Pai-Silva, Maeli, "Aerobic Exercise Training Prevents Heart Failure-Induced Skeletal 
Muscle Atrophy by Anti-Catabolic, but Not Anabolic Actions" (2014). Nutrition and Health Sciences -- 
Faculty Publications. 277. 
https://digitalcommons.unl.edu/nutritionfacpub/277 
This Article is brought to you for free and open access by the Nutrition and Health Sciences, Department of at 
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Nutrition and Health 
Sciences -- Faculty Publications by an authorized administrator of DigitalCommons@University of Nebraska - 
Lincoln. 
Authors 
Rodrigo W.A. Souza, Warlen P. Piedade, Luana C. Soares, Paula A. T. Souza, Andreo F. Aguiar, Ivan Jose 
Vechetti Jr, Dijon H.S. Campos, Ana A. H. Fernandes, Katashi Okoshi, Robson F. Carvalho, Antonio C. 
Cicogna, and Maeli Dal-Pai-Silva 
This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/
nutritionfacpub/277 
Aerobic Exercise Training Prevents Heart Failure-Induced
Skeletal Muscle Atrophy by Anti-Catabolic, but Not
Anabolic Actions
Rodrigo W. A. Souza1, Warlen P. Piedade1, Luana C. Soares1, Paula A. T. Souza1, Andreo F. Aguiar4,
Ivan J. Vechetti-Júnior1, Dijon H. S. Campos2, Ana A. H. Fernandes3, Katashi Okoshi2,
Robson F. Carvalho1, Antonio C. Cicogna3, Maeli Dal-Pai-Silva1*
1Department of Morphology, São Paulo State University, Botucatu, São Paulo, Brazil, 2Department of Internal Medicine, São Paulo State University, Botucatu, São Paulo,
Brazil, 3Department of Biochemistry, São Paulo State University, Botucatu, São Paulo, Brazil, 4Centre of Biological and Health Sciences, North University of Paraná,
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Abstract
Background: Heart failure (HF) is associated with cachexia and consequent exercise intolerance. Given the beneficial effects
of aerobic exercise training (ET) in HF, the aim of this study was to determine if the ET performed during the transition from
cardiac dysfunction to HF would alter the expression of anabolic and catabolic factors, thus preventing skeletal muscle
wasting.
Methods and Results: We employed ascending aortic stenosis (AS) inducing HF in Wistar male rats. Controls were sham-
operated animals. At 18 weeks after surgery, rats with cardiac dysfunction were randomized to 10 weeks of aerobic ET (AS-
ET) or to an untrained group (AS-UN). At 28 weeks, the AS-UN group presented HF signs in conjunction with high TNF-a
serum levels; soleus and plantaris muscle atrophy; and an increase in the expression of TNF-a, NFkB (p65), MAFbx, MuRF1,
FoxO1, and myostatin catabolic factors. However, in the AS-ET group, the deterioration of cardiac function was prevented,
as well as muscle wasting, and the atrophy promoters were decreased. Interestingly, changes in anabolic factor expression
(IGF-I, AKT, and mTOR) were not observed. Nevertheless, in the plantaris muscle, ET maintained high PGC1a levels.
Conclusions: Thus, the ET capability to attenuate cardiac function during the transition from cardiac dysfunction to HF was
accompanied by a prevention of skeletal muscle atrophy that did not occur via an increase in anabolic factors, but through
anti-catabolic activity, presumably caused by PGC1a action. These findings indicate the therapeutic potential of aerobic ET
to block HF-induced muscle atrophy by counteracting the increased catabolic state.
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Introduction
Cardiac dysfunction precedes heart failure (HF) and is typically
characterized by enlargement of the heart and increased myocyte
cell volume [1]. Pathological hypertrophy of the myocardium
temporarily preserves its pump function, although prolongation of
this state is a leading predictor of HF [1]. HF is the main cause of
hospitalization and death worldwide. In the terminal phase of HF,
a complex metabolic syndrome called cardiac cachexia, which is
characterized by a loss of muscle and fat mass that is unresponsive
to nutritional supplementation alone and which has been
identified as a strong independent risk factor for mortality, is
often observed [2]. However, the process leading to the
progressive muscle atrophy that ultimately results in cardiac
cachexia is still not completely understood.
Skeletal muscle atrophy is related to endocrine disorders and
inflammatory conditions that can induce hypertrophy and
atrophy-related gene/protein expression. Considerable evidence
suggests that neurohormonal and immune mechanisms may play a
central role in the pathogenesis of HF by controlling the balance
between pro- and anti-growth signals in the skeletal muscle.
Several factors have been demonstrated to be responsible for
muscle wasting during HF, including reduced local insulin-like
growth factor I (IGF-I) expression [3], increased muscular tumor
necrosis factor alpha (TNF-a) [4], increased myostatin expression
[5], and overexpression of the E3-ligases Muscle RING Finger 1
(MuRF-1) and atrogin-1/Muscle Atrophy F-Box (MAFbx), which
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activate the ubiquitin–proteasome system [6]. However, a direct
effect of humoral factors on muscle-mass regulators during HF has
not been well established.
In HF, alterations in multiple anabolic and catabolic systems
result in progressive catabolism, which leads to skeletal muscle
atrophy in advanced stages of the disease [7,8]. IGF-I/AKT/
mTOR is an essential regulator of skeletal muscle capacity for
protein synthesis and degradation [9]. In the canonical IGF-I/
AKT/mTOR pathway, AKT activation of mTOR and the
subsequent phosphorylation of p70S6K and 4E-BP1 induce
protein synthesis. In the early stages, chronic HF-related muscle
atrophy is associated with reduced expression of IGF-I [10]. In
addition to protein synthesis, the IGF-I pathway inhibits protein
degradation through the sequestration of the forkhead box O
(FoxO) family of transcription factors in the cytoplasm, where they
are transcriptionally inactive [11]. In skeletal muscle, FoxO1 and 3
activation have been observed under conditions of muscle atrophy,
such as cachexia [12] and HF [13], thereby promoting the
transcription of atrophy-related genes. However, FoxO-induced
muscle atrophy activity is also modulated by other intracellular
signaling molecules, such as peroxisome proliferator-activated
receptor-c coactivator-1a (PGC1a), a regulator of skeletal muscle
mass, particularly in conditions of muscle atrophy [14]. Significant
evidence has demonstrated that increased PGC1a expression is
sufficient to inhibit in vivo FoxO3-induced muscle fiber atrophy
and that transgenic muscle-specific PGC1a overexpression pro-
tects against denervation- and fasting-induced atrophy, an effect
associated with a reduction of the expression of MAFbx, MuRF1,
and cathepsin L [14].
Exercise training (ET) is a widely accepted and widely proposed
nonpharmacological intervention to minimize the symptoms of
HF [15]. In humans, ET has been shown to directly improve
metabolic and functional abnormalities of the peripheral muscles
without changing cardiac performance [16]. In addition, ET has
anti-inflammatory effects, with the potential to reduce local
cytokine expression (e.g., TNF-a, IL-1b, and IL-6) [4] and
increase the expression of anti-apoptotic factors (e.g., myostatin)
[17], indicating that this type of intervention could partially
reverse the catabolic state in skeletal muscle.
While the potential beneficial effects of ET on the loss of muscle
mass in HF are clear, the exact molecular mechanisms by which
ET might delay the onset of cardiac cachexia in the HF remain
unclear. Therefore, the aim of the present study was to examine
the effects of ET during the transition from cardiac dysfunction to
HF on the expression of muscle mass-related anabolic and
catabolic factors. We hypothesized that ET would increase
anabolic factor expression and decrease catabolic factor expres-
sion, thus preventing muscle wasting during the transition from
cardiac dysfunction to HF.
Materials and Methods
Animal Care and Experimental Design
All experiments and procedures were performed in accordance
with the Guide for the Care and Use of Laboratory Animals
published by the U.S. National Institute of Health and were
approved by the Animal Ethics Committee, São Paulo State
University (#198). Three- to four-week-old male Wistar rats
weighing 90–100 g were anesthetized with a mixture of ketamine
(50 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.). A total of 16 rats
was submitted to aortic stenosis (AS) surgery, which involved
placing a 0.6-mm-i.d. stainless steel clip on the ascending aorta via
a thoracic incision [1]. A total of 16 age-matched control animals
underwent left thoracotomy without clip placement (Sham group).
The rats were housed in collective polypropylene cages (2 animals
per cage) covered with metallic grids in a temperature-controlled
room (22–24uC) under a reverse light cycle (the dark cycle began
at 7:00 a.m., and the light cycle began at 7:00 p.m.). The animals
were given standard rat chow (Labina; Purina, SP, Brazil) and
water ad libitum.
At 18 weeks after surgery, when the AS animals presented a
cardiac dysfunction as measured by echocardiography, both
groups (Sham and AS) were randomly redistributed in either
sedentary untrained groups (Sham-UN, n= 8, and AS-UN, n= 8)
and groups that underwent to 10 weeks of aerobic ET protocol
(Sham-ET, n= 8, and AS-ET, n= 8). The ET protocol is
described in detail below. Our laboratory has previously demon-
strated that rats with AS start to exhibit evidence of HF
approximately 21–25 weeks after surgery [18,19]. Thus, after 28
weeks, all 4 groups underwent another echocardiogram and were
then euthanized. The experimental design is shown in Figure 1. At
the time of euthanasia, the rats were weighed and anesthetized
with intraperitoneal pentobarbital sodium (50 mg/kg). The heart
was removed via thoracotomy, and the atria and ventricles were
separated and weighed. The soleus and plantaris muscles, which
were chosen because of their contrasting structural and metabolic
characteristics (i.e., fiber type distribution and prevalent metabo-
lism), were harvested, rapidly frozen in isopentane cooled by liquid
nitrogen, and subsequently stored at 280uC. For the HF
examination, 2 observers determined the presence or absence of
clinical and pathological HF features at the time of euthanasia.
The clinical finding suggestive of HF was tachypnea and labored
respiration. The pathological assessment of cardiac decompensa-
tion included left atrial thrombi, pulmonary congestion (lung
weight/body weight ratio.2 SD above the mean for the Sham-
UN group), right ventricular hypertrophy, ascites, and hepatic
congestion [20]. In this study, rats with atrial thrombi, pulmonary
congestion, and/or right ventricular hypertrophy were considered
to have HF [21].
Lactate Threshold Determination
To determine their lactate threshold and the velocity at which
the lactate threshold occurred, the animals allocated into the
exercise training study were subjected to incremental exercise
testing on a motor treadmill adapted to experimental models [22].
The lactate threshold was defined as the running velocity that
could be maintained without a lactate increase of 1.0 mmol/L
above the blood lactate concentration obtained at the previous
speed [23]. The protocol used for the incremental load test was
adapted from that previously described by Carvalho et al. [24] and
was performed at the end of Week 1 (week of adaptation), Week 4,
and Week 7.
After a 1-week (10 min/day) adaption to the treadmill exercises,
the rats were submitted to exercise testing. The treadmill speed
started at 6 m/min and was progressively increased by 3 m/min
every 3 min at 0% grade until exhaustion, which was defined as
the point at which the rats could no longer maintain a running
speed over 3 min. After each load increase, the animal was
manually removed from the treadmill for 1 min for blood
collection. Blood samples were taken from the tail vein and was
pipetted evenly onto a test strip, which was inserted into a portable
lactate analyzer (Accutrend Lactate, Boehringer-Mannheim)
[25,26]. The equipment was calibrated with a code strip specific
to each lactate determination package.
Aerobic Exercise Training
Rats in the training groups, Sham-ET and AS-ET, performed
an aerobic ET program for 10 weeks (5 days/week). The program
Exercise Training Prevents Muscle Atrophy during Heart Failure
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was modified from those previously described by De Souza et al.
[27] and Siu et al. [28]. The duration and intensity of the training
sessions progressively increased from 5 min, 5 m/min (Sham-ET
and AS-ET, 1st week) to 10, 12, and 14 min, 9 m/min (Sham-ET)
and 6 m/min (AS-ET, 2nd to 4th week); 16, 18 and 20 min, 18 m/
min (Sham-ET) and 12 m/min (AS-ET, 5th to 7th week); 20, 22
and 22 min, 21 m/min (Sham-ET) and 15 m/min (AS-ET, 8th to
10th week). The running speed corresponded to the lactate
threshold, which was determined by the incremental exercise test
(described above) performed at the end of Weeks 1, 4, and 7 to
adjust the training velocities. The training sessions were performed
at the same time of day, between 2 and 4 p.m.
Echocardiographic Study
Echocardiographic measurements were performed before and
after aerobic ET using a commercially available echocardiograph
(General Electric Medical Systems, Vivid S6, Tirat Carmel, Israel)
equipped with a 5–11.5 MHz multifrequency transducer. Rats
were anesthetized by intramuscular injection of a mixture of
ketamine (50 mg/kg) and xylazine (0.5 mg/kg) and positioned in
supine position and ultrasound transmission gel was applied to the
precordium. A two-dimensional parasternal short-axis view of the
left ventricle (LV) was obtained at the level of the papillary
muscles. M-mode tracings were obtained from short-axis views of
the LV at or just below the tip of the mitral-valve leaflets, and at
the level of the aortic valve and left atrium. All LV structures were
manually measured by the same observer according to the leading-
edge method of the American College of Echocardiography [29].
The measurements obtained were the mean of at least five cardiac
cycles on the M-mode tracings. The following structural variables
were measured: left atrium (LA) diameter, LV diastolic and systolic
dimensions (LVDD and LVSD, respectively), LV diastolic
posterior wall thickness (PWT), LV relative thickness in diastole
(RWT; calculated as 2*PWT/LVDD), and aortic diameter (AO).
Left ventricular function was assessed by the following parameters:
heart rate (HR), endocardial fractional shortening (FS), LV
ejection fraction (EF), posterior wall shortening velocity (PWSV),
and early-to-late diastolic mitral inflow ratio (E/A ratio).
Muscles and Histochemical Procedures
Serial histological sections (12 mm thick) from soleus and
plantaris muscles were obtained in a cryostat (JUNG CM1800,
Leica Germany) at 224uC to histochemical analysis. To
determine muscle fiber-type frequency and cross sectional area
(CSA) myofibrillar adenosine triphosphatase (mATPase) histo-
chemistry was performed after preincubation at pH 4.2, 4.5 and
10.6 [30]. Muscle fibers (Type I, IIA, IID, and IIB) were identified
based on their staining intensities [31] (Figure 2). The stained
sections were used for photographic documentation of 4 histolog-
ical fields (400 random fibers; 206lens) from soleus and plantaris
muscles of each animal. Fiber type frequency and CSA (used as an
index of type-specific fiber atrophy) were analyzed using an Image
Analysis System Software (Leica QWin Plus, Germany).
Serum TNF-a and IGF-I Levels
TNF-a and IGF-I levels were analyzed by enzyme-immuno-
metric using a commercially available kits (Quantikine Rat TNF-a
Immunoassay, and Quantikine Mouse/Rat IGF-I Immunoassay,
R & D Systems, Minneapolis, MN) and the procedures were
performed according to manufacturer’s instructions. All the
samples were run in duplicate and the average values are reported.
Biochemical Assay Procedures
Soleus and plantaris muscle samples (200 mg) were homoge-
nized in 5 ml cold phosphate buffer (0.1 mmol/L, pH 7.4) using a
motor-driven Teflon glass Potter-Elvehjem (1 min, 1006g). The
whole homogenate was centrifuged at 10,0006g for 15 min, and
the supernatant was used for determination of lactate dehydroge-
nase (LDH; E.C.1.1.1.27) and citrate synthase (CS; E.C.4.1.3.7).
CS was measured in a medium containing 50 mmol/L Tris-HCl
pH 8.1, 0.3 mmol/L acetyl-CoA, 0.1 mmol/L DTNB (5,59
dithiobia-2-nitrobenzoic acid), and 0.5 mmol/L oxaloacetate,
according to Bass and colleagues [32]. The assay medium for
LDH contained 50.0 mmol/L Tris-HCl buffer pH 7.5,
0.15 mmol/L nicotinamide adenine dinucleotide reduced form
(NADH), and 1 mmol/L pyruvate, as previously described [33].
Enzyme activities were performed at 25uC using a microplate
reader (mQuant-MQX 200 with Kcjunior software to computer
system control, Bio-Tec Instruments, Winooski, Vermont, USA).
All chemicals and solvents were from Sigma (St. Louis, Missouri,
USA).
Quantitative Real-time PCR
Total RNA was extracted from soleus and plantaris muscles
using Trizol Reagent (Life Technologies, CA, USA), solubilized in
nuclease-free water and quantified (NanoVue Plus; GE Health-
Care, Little Chalfont, UK). After assessment of RNA concentra-
tion (ng/ml), purity (ensured by 260/280 nm ratio of ,2.0) and
Figure 1. Experimental design. Sham, control group; AS, animals submitted to aortic stenosis surgery; Sham-UN, control untrained group; Sham-
ET, control exercise training group; AS-UN, aortic stenosis untrained group; AS-ET, aortic stenosis exercise training group.
doi:10.1371/journal.pone.0110020.g001
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integrity (RNA integrity number .8; RNA 6000 Nano assay;
Agilent, Waldbronn, Germany), the RNA was treated with
Amplification Grade Deoxyribonuclease I (Life Technologies,
Carlsbad, CA, USA) to remove any genomic DNA contamination.
cDNA was synthesized using High Capacity cDNA Reverse
Transcription Kit (Life Technologies, Carlsbad, CA, USA)
according to the manufacturer’s protocols, and the genes involved
in atrophic system, as TNF-a (Rn00562055_m1), NFkB
(Rn01502266_m1), MAFbx (Rn00591730_m1), MuRF1
(Rn00590197_m1), FoxO1 (Rn01494868_m1) and myostatin
(Rn00569683_m1); hypertrophic system IGF-I
(Rn00710306_m1), AKT1 (Rn00583646_m1) and mTOR
(Rn00571541_m1) and anti-proteolytic PGC1a
(Rn00580241_m1) were analyzed. All genes were measured by
real-time quantitative PCR (RT-qPCR) using microfluidic Taq-
Man Low Density Array (TLDA; Life Technologies, Carlsbad,
CA, USA) cards. Five control genes were tested 18S rRNA
(Hs99999901_s1), Actb (Rn00667869_m1), Gapdh
(Rn01775763_g1), Hprt1 (Rn01527840_m1) and Tbp
(Rn01455648_m1) and Hprt1, Actb and Tbp were used as
reference genes to normalize the data as they recorded the highest
stability. A total of 100 ml reaction mixture with 50 ml of cDNA
template (200 ng mRNA) was added to 50 ml of TaqMan
Universal PCR Master Mix (Applied Biosystems, Foster City,
CA, USA) and was dispensed into loading wells on the TLDA
card. The cards were centrifuged twice at 1,200 rpm for 1 min
each time, sealed, and placed in the thermal cycler. The following
cycling conditions were used for all TLDA applications: 50uC for
2 min, 95uC for 10 min, and 40 cycles of 95uC for 15 s followed
by 60uC for 1 min and thermal cycling and fluorescence detection
was performed on Applied Biosystems ABI Prism ViiA7 Sequence
Detection System with ABI Prism ViiA7 SDS Software 2.4.
TLDAs data were analyzed using the DataAssist software 2.0 (Life
Technologies).
Western blot
Protein levels of TNF-a, NFkB (p65), MAFbx, MuRF1, FoxO1,
Phospho-FoxO1 (Ser256), myostatin, IGF-I, AKT, Phospho-AKT
(Ser473), mTOR, Phospho-mTOR (Ser2448), PGC1a and Gapdh
were quantified by Western blot assays in soleus and plantaris
muscle extracts. Muscle samples were homogenised in lysis buffer
(1% Triton X-100, 10 mM sodium pyrophosphate, 100 mM NaF,
10 mg/mL aprotinin, 1 mM phenylmethylsulfonylfluoride
(PMSF), 0.25 mM Na3VO4, 150 mM NaCl and 50 mM Tris-
HCl pH 7.5). The samples were centrifuged and 50 mL of the
homogenate fraction were resuspended in 25 mL of Laemmli
loading buffer (2% SDS, 20% glycerol, 0.04 mg/mL bromophe-
nol blue, 0.12 M Tris-HCl pH 6.8, and 0.28 M b-mercaptoeth-
anol). Fifty micrograms of total protein were separated by one-
dimensional SDS-PAGE, stained with Ponceau S red (Sigma
Chemical) to confirm equal loading of each sample. As a second
approach to verify similar loading between the lanes, gels were
loaded in duplicate, and one gel was stained with Coomassie blue.
Proteins were transferred from a gel to a nitrocellulose membrane
(Bio-Rad Laboratories, Hercules, CA, USA). Using a vacuum-
enhanced detection system (SNAP i.d., Millipore, Billerica, MA,
USA) nonspecific binding sites were blocked with a 3% bovine
serum albumin (BSA) solution in phosphate-saline buffer (PBS-T:
0.1 M NaH2PO4?H2O, 0.1 M Na2HPO4?7H2O, 0.15 M NaCl,
0.1% Tween-20, pH 7.4) for 10 minutes. Following blocking, the
membranes were incubated with specific primary antibodies
against TNF-a (Santa Cruz, California, USA; #sc-1349), NFkB
- p65 (Santa Cruz, California, USA; #sc-8008), MAFbx (Santa
Cruz, California, USA; #sc-27644), MuRF1 (Santa Cruz,
California, USA; #sc-27642), FoxO1 (Cell Signaling, Beverly,
USA; #9454), myostatin (Santa Cruz, California, USA; #sc-
6884), Phospho-FoxO1 (Cell Signaling, Beverly, USA; #9461),
IGF-I (Santa Cruz, California, USA; #sc-7144), AKT (Cell
Signaling, Beverly, USA; #9272), Phospho-AKT (Cell Signaling,
Beverly, USA; #4060), mTOR (Cell Signaling, Beverly, USA;
#2972), Phospho-mTOR (Cell Signaling, Beverly, USA; #5536),
PGC1a (Abcam, Cambridge, UK; ab-106814) and Gapdh (Cell
Signaling, Beverly, USA; #2118) in a 1% BSA solution for
10 min. After four wash steps with PBS-T, membranes were
incubated in a 1:2,000 dilution of specific secondary antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) conjugated
with horseradish peroxidase for 10 min. Finally, immunoreactive
protein signals were detected using SuperSignal West Pico
Chemiluminescent Substrate Kit (Thermo Fisher Scientific, Rock-
ford, IL, USA), according to the manufacturer’s instructions. The
chemiluminescent signal was visualized and quantified by densi-
tometry using the image analyzer ImageQuant 350 (GE
Healthcare, Little Chalfont, UK). The values were normalized
by the values obtained for Gapdh protein.
Statistical Analysis
Data are expressed as mean 6 SD. Shapiro-Wilk normality test
was used to verify data normal distribution. Differences in
echocardiographic parameters before aerobic ET between Sham
and AS animals were tested with unpaired Student’s t test. The
muscle fiber type frequency data were analyzed using Kruskal-
Wallis test. One-way analysis of variance (ANOVA) followed by a
posteriori Tukey multiple comparison test was used to analyze
circulating TNF-a, CSA, CS, LDH, mRNA and protein
expression data after ET among the groups. To analyze the
involvement of exercise on cardiac parameters between before and
after aerobic ET, echocardiographic values were probed with two-
way ANOVA for repeated measures with a Bonferroni’s post test.
Linear regression was used to assess the relationship between
PGC1a - FoxO1 mRNA and protein expression in the plantaris
Figure 2. Serial cross sections of the rat hindlimb muscles. Soleus (a) and plantaris (b, c and d) muscles taken from a Sham-UN group rat
demonstrating fiber-type delineation as determined by the myofibrillar adenosine triphosphatase (mATPase) reaction after preincubation at pH 4.2
(b), 4.5 (a, c), and 10.6 (d). (I, type I; A, type IIA; D, type IID; and B, type IIB).
doi:10.1371/journal.pone.0110020.g002
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muscle. Statistical significance was considered achieved when the
value of p was ,0.05.
Results
Clinical and Anatomical Parameters
Relevant anatomical data are summarized in Table 1. At 18
weeks post-surgery and before the aerobic ET period, all the AS
rats displayed deterioration of cardiac structure and function but
did not present HF signs. In this study, an HF diagnosis was based
on the presence of tachypnea and labored respiration and
confirmed by pathological post mortem findings, such as right
ventricular hypertrophy, pulmonary congestion, left atrial throm-
bus, and ascites. At 28 weeks after surgery, six of 8 AS-UN animals
showed severe ascites, moderate tachypnea and atrial thrombi;
however, the AS-ET animals presented a reduced intensity and
frequency of these signs. Of the 8 AS-ET rats, three had mild
ascites and tachypnea and only one presented atrial thrombi.
Although the LV weight and LV/BW ratio were increased in both
of the AS groups, the ET period attenuated the presence of cardiac
thrombi and the increase in the atria, right ventricle, and lung
weights in both absolute and BW-normalized values.
Cardiac Geometry, Function and Running Performance
To evaluate cardiac function, all the animals were submitted to
an echocardiographic study before and after the aerobic ET
protocol (Table 2). Before ET, AS groups showed pathological
cardiac remodeling evidenced by increased PWT and RWT, while
cardiac dysfunction was demonstrated by a decrease in PWSV and
an elevation of the mitral E/A wave and LA/AO ratios. No
change in heart rate (HR) under anesthesia was observed,
indicating that the depth of anesthesia was similar among the
groups during the echocardiographic examination. At the end of
the experiment, the AS-UN group displayed a deterioration of
cardiac dysfunction compared with the AS group at 18-weeks as
shown by significant LV dilation at systole (LVSD) and diastole
(LVDD) and accompanied by an increased PWT and E/A wave
ratio. Furthermore, after 10 weeks of the training period, the left
ventricular PWSV, endocardial FS and EF deteriorated even
further in the AS-UN group compared with the preprotocol 18-
week AS rats.
The echocardiographic parameters remained unchanged in the
AS-ET group after aerobic ET. Moreover, in the AS-ET the ET
protocol prevented contractile dysfunction (decreased FS) and
ejection fraction (EF) and avoided increases in the LV diameter at
systole and diastole compared with the AS-UN group. In addition,
we observed improved exercise tolerance and performance, as
demonstrated by a significant increase in velocity at the lactate
threshold in the Sham-ET and AS-ET groups between the Week 1
and Week 7 tests (Figure 3).
Citrate Synthase and Lactate Dehydrogenase Activities
The activities of the enzymes citrate synthase (CS) (an indicator
of cellular aerobic metabolism) and lactate dehydrogenase (LDH)
(an indicator of anaerobic metabolism) were measured in soleus
and plantaris muscle samples obtained from all groups after
aerobic ET. HF induced a significant decrease (25%) in CS
activity in both muscles in the AS-UN group compared with the
Sham-UN group. CS maximal activity was similar within ET rats
studied (Sham-ET and AS-ET), moreover, CS activity was
preserved in AS-ET group when compared with AS-UN,
suggesting that oxidative metabolism was improved, enhancing
the muscle performance (Figure 4, A and C). LDH activity in the
plantaris muscle was significantly increased in the AS-UN group
compared with the Sham-UN group (Figure 4D), while the AS-ET
group remained unchanged. In the soleus muscle, no significant
difference was observed in LDH enzyme activity among the
groups (Figure 4B).
Muscle Fiber Type Frequency and Cross-Sectional Area
Using the histochemical reaction of myofibrillar ATPase (m-
ATPase), we observed that aerobic ET performed between cardiac
dysfunction and HF prevented in 16% the reduction in the
percentage of slow-twitch fibers (i.e., Type I) and Type I-to-Type
IIA fiber conversion in the soleus muscle of the AS-ET rats
(Figure 5A). In the plantaris muscle, ET attenuated the decrease in
Type IIA fibers to approximately 22%, and it decreased the Type
IIA-to-Type IID fiber conversion in AS-ET compared to AS-UN
group (Figure 5B). To determine if the aerobic ET subjected
Table 1. Anatomical data after exercise training.
Sham-UN (n=8) Sham-ET (n =8) AS-UN (n=8) AS-ET (n =8)
BW (g) 489629 475648 464636 440645
LV (g) 0.7760.07 0.6560.07 1.1560.15* 1.0660.13#
LV/BW (mg/g) 1.5760.18 1.3760.20 2.5360.23* 2.4560.22#
RV (g) 0.2560.05 0.2460.03 0.4660.10* 0.3560.09
RV/BW (mg/g) 0.5260.09 0.5160.04 1.0060.26* 0.8660.25
Atria (g) 0.1160.03 0.1060.01 0.4060.08* 0.2860.09#{
Atria/BW (mg/g) 0.2360.06 0.2060.02 0.8760.17* 0.6460.22#{
Incidence of cardiac thrombi 0% 0% 56% 11%
Lung (g) 1.9260.44 1.8960.20 3.2560.62* 2.5260.59{
Lung/BW (mg/g) 3.9260.93 4.0060.54 7.1661.53* 5.4961.17{
Sham and aortic stenosis rats that remained untrained (UN) or were submitted to aerobic exercise training (ET) during the 10 weeks of training protocol; AS-ET, aortic
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between cardiac dysfunction and HF was able to prevent atrophy
of the soleus and plantaris muscles, we used the m-ATPase
reaction to measure the skeletal muscle fiber cross-sectional area
(CSA). At the end of the experiment, the AS-UN group presented
a significant reduction in the CSA of Type I and IIA fibers in the
soleus muscle (Table 3). Moreover, in this muscle, aerobic ET
attenuated the reduction of fibers CSA in AS-ET animals. On the
other hand, Type I and IIA fibers of plantaris muscle were not
affected by AS and ET stimuli. However, a significant decrease in
the CSA of plantaris Type IID and IIB fibers was observed in the
AS-UN group, indicating that ET prevented the atrophy of
plantaris Type IID and IIB fibers (Table 4).
Figure 3. Blood lactate concentration in the AS-ET and Sham-ET groups assessed on the 1st, 4th and 7th weeks by incremental load
test. Values are expressed as the mean6 SD. Significant differences (p,0.05) at the same time were in AS-ET group: a. vs. 9 m/min; b. vs. 15 m/min;
and c. vs. 18 m/min. Sham-ET: d. vs. 12 m/min; e. vs. 21 m/min; and f. vs. 24 m/min.
doi:10.1371/journal.pone.0110020.g003
Figure 4. CS and LDH activities. Soleus (A and B) and plantaris (C and D) muscles of the Sham-UN, Sham-ET, AS-UN, and AS-ET groups. Data are
presented as the mean 6 SD. *p,0.05 vs. Sham-UN; {p,0.05 vs. AS-UN.
doi:10.1371/journal.pone.0110020.g004
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Systemic Concentration of TNF-a and IGF-I
The serum concentration of TNF-a showed a significant
increase only between the non-trained HF animals (AS-UN
group) and Sham-UN group (AS-UN: 18.0463.96 pg/mL vs.
Sham-UN: 12.0761.67 pg/mL; p,0.05). However, AS-ET group
still remained not significantly lower than of the AS-UN group
(Figure 6A). On the other hand, the serum concentration of IGF-I
was significantly lower in the non-trained rats (AS-UN group) as
compared to Sham-UN (AS-UN: 918.76123.2 pg/mL vs. Sham-
UN: 1328.06143.7 pg/mL, p,0.05); the trained rats (AS-ET)
remained not significantly higher than the sedentary rats
(Figure 6B).
Skeletal Muscle Gene and Protein Expression
Proteolytic system. To investigate the effects of ET on
changes in the skeletal muscle proteolytic system in HF animals,
Figure 5. Soleus (A) and plantaris (B) muscle fiber-type frequencies. Representative photographs of mATPase reaction after preincubation at
pH 4.5 and the data of the muscle fiber-type frequencies in Sham-UN, Sham-ET, AS-UN, and AS-ET groups. (Type I; type IIA; type IID; and type IIB).
Soleus (A), type I and IIA *p,0.05 vs. Sham-UN; {p,0.05 vs. AS-UN. Plantaris (B), type IIA and IID, *p,0.05 vs. Sham-UN; {p,0.05 vs. AS-UN.
doi:10.1371/journal.pone.0110020.g005
Table 3. Cross sectional area (mm2) of the two major soleus muscle fiber types after ET.
Sham-UN (n=8) Sham-ET (n=8) AS-UN (n=8) AS-ET (n =8)
I 3564.096307.87 3582.966204.80 3056.926281.86* 3565.186376.28{
IIA 3485.776232.03 3755.206359.61 2950.676223.70* 3976.286408.96{
Data are expressed as mean 6 SD.
*p,0.05 vs. Sham-UN;
{p,0.05 vs. AS-UN.
One-way ANOVA + Tukey test.
doi:10.1371/journal.pone.0110020.t003
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we measured the mRNA and protein levels of TNF-a, NFkB
(p65), MAFbx, MuRF1, FoxO1, and myostatin in the soleus and
plantaris muscles (Figure 7). Furthermore, the catabolic effect of
HF on skeletal muscle was assessed by the phosphorylation status
of FoxO1Ser256 in Sham-UN, Sham-ET, AS-UN and AS-ET rats.
In the soleus muscle, there was a significant (p,0.05) increase in
TNF-a, NFkB (p65), FoxO1, and myostatin gene (Figure 7A) and
protein (Figure 7B and C) expression in the AS-UN group
compared to the Sham-UN group (Figure 7B and C). Interest-
ingly, this upregulation in catabolic factor expression was
attenuated in the AS-ET group (Figure 7A and B) in conjunction
with an increase in the phosphorylation levels of FoxO1Ser256. In
addition, MAFbx mRNA was significantly increased, and the
increases in MAFbx and MuRF1 protein content in the AS-UN
group were significantly attenuated in the AS-ET group
(Figure 7B and C). In the plantaris muscle (Figure 7D, E, and
F), we observed a significant (p,0.05) increase in TNF-a and
FoxO1 gene and protein expression in the AS-UN group and a
decrease in the ratios of phosphorylated FoxO1 protein to total
protein expression and a significant attenuation in the AS-ET
group. Furthermore, a significant increase in myostatin gene and
protein expression was observed in the AS-UN group, and
attenuation of this increase at the protein level was observed in the
AS-ET group. In addition, MAFbx gene and protein expression
were increased in the AS-UN group compared with the Sham-UN
group, but no significant effect of ET was observed in the AS-ET
group. NFkB (p65) mRNA expression was increased in the AS-
UN group and attenuated in the AS-ET group. Moreover, AS-UN
group showed not significantly higher in MuRF1 gene and protein
expression and attenuated protein levels in the AS-ET group.
Hypertrophy Pathway. To determine if ET stimulates the
hypertrophic pathway and attenuates the atrophic effect observed
in skeletal muscles in our HF model, we measured IGF-I
expression and its downstream AKT and mTOR. Our results
indicated that there were no differences (p.0.05) in IGF-I mRNA
and protein levels in the soleus (Figure 8A and B) and plantaris
(Figure 8D and E) muscles among the groups. Similarly, no
changes in AKT and mTOR mRNA and the ratios of
phosphorylated protein to total protein expression occurred
among the groups in either muscle type (Figure 8).
Anti-Proteolytic Component. To explore additional aspects
of the prevention of skeletal muscle loss in HF via ET, PGC1a
expression was investigated. As shown in Figure 9, although no
statistically significant differences were observed in the soleus
muscle, in the plantaris muscles, we observed a decrease in PGC1a
mRNA levels in approximately 62% of the AS-UN animals
(Figure 9D); furthermore, PGC1a protein levels were approxi-
mately 55% lower in the AS-UN animals compared with the other
groups (Figure 9E and F). Interestingly, the AS-ET rats displayed
significant attenuation of the reduction in PGC1a mRNA and
protein levels, which remained at the same levels as in the Sham-
ET group. In addition, linear regression analysis of the plantaris
muscle results revealed a significant negative correlation between
FoxO1 and PGC1a mRNA expression (Pearson’s r=20.69,
p = 0.003) and FoxO1 and PGC1a protein levels (Pearson’s r=2
0.90, p,0.0001), based on an analysis of the individual data points
for the AS-UN and AS-ET groups (Figure 10).
Table 4. Cross sectional area (mm2) of plantaris muscle fiber types after ET.
Sham-UN (n=8) Sham-ET (n =8) AS-UN (n=8) AS-ET (n =8)
I 2317.286247.10 2223.106231.19 2270.526426.69 2158.096378.18
IIA 2229.726165.23 2222.166186.57 2141.536298.37 2246.696282.28
IID 2703.846272.88 2716.396184.22 2307.126276.74* 2679.916303.61{
IIB 4159.276397.15 4357.316405.12 3508.916228.85* 4273.556490.45{
Data are expressed as mean 6 SD.
*p,0.05 vs. Sham-UN;
{p,0.05 vs. AS-UN.
One-way ANOVA + Tukey test.
doi:10.1371/journal.pone.0110020.t004
Figure 6. Serum concentration. Proinflammatory cytokine TNF-a (A) and growth factor IGF-I (B) in AS-UN, AS-ET, Sham-UN, and Sham-ET groups.
Data are presented as the mean 6 SD. *p,0.05 vs. Sham-UN.
doi:10.1371/journal.pone.0110020.g006
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Figure 7. mRNA and protein levels of the skeletal muscle proteolytic system. A and D: mRNA levels in the soleus (A) and plantaris (D)
muscles; protein content in the soleus (B) and plantaris (E) muscles; representative blots of soleus (C) and plantaris (F) muscles in Sham-UN, Sham-ET,
AS-UN, and AS-ET groups. Data are expressed as the mean 6 SD; *Significant difference from the Sham-UN group, p,0.05; #p,0.05 vs. Sham-ET;
{p,0.05 vs. AS-UN group.
doi:10.1371/journal.pone.0110020.g007
Figure 8. mRNA and protein levels of skeletal muscle hypertrophy components. A and D: mRNA levels in the soleus (A) and plantaris (D)
muscles; protein content in the soleus (B) and plantaris (E) muscles; representative blots of soleus (C) and plantaris (F) muscles from Sham-UN, Sham-
ET, AS-UN, and AS-ET groups. Data are expressed as the mean6 SD; *Significant difference from the Sham-UN group, p,0.05;#p,0.05 vs. Sham-ET;
{p,0.05 from the AS-UN group.
doi:10.1371/journal.pone.0110020.g008
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Discussion
Metabolic abnormalities resulting in a progressive catabolic
state have been observed in various chronic diseases [34,35]. Since
skeletal muscle dysfunction and loss of lean muscle mass have been
described in HF [36,37], a number of studies have focused on
identifying therapies that could improve clinical outcomes. Studies
of HF have reported that ET is an effective non-pharmacological
therapy for improving exercise capacity and quality of life and
confers survival benefits [38]. Moreover, recent reports have
demonstrated that ET has beneficial effects against HF-induced
skeletal myopathy [39,40]. However, the molecular mechanisms
by which ET attenuates or reverses skeletal muscle myopathy,
which would become attractive targets for heart failure therapy,
remain elusive.
In the present study, we used the ascending aortic stenosis (AS)
model to promote a gradual development of left ventricular
hypertrophy and posterior HF in rats [1]. In this model, animals
develop cardiac remodeling that is associated, in the short term,
with diastolic dysfunction and improved systolic function, followed
by depressed systolic performance and HF. After 18 weeks of
supra-aortic stenosis and before the training intervention, cardiac
Figure 9. mRNA and protein levels of the skeletal muscle proteolysis inhibitor PGC1a. A and D: mRNA levels in the soleus (A) and plantaris
(D) muscles; protein content in the soleus (B) and plantaris (E) muscles; representative blots of soleus (C) and plantaris (F) muscles in Sham-UN, Sham-
ET, AS-UN, and AS-ET groups. Data are presented as the mean 6 SD; *Significant difference from the Sham-UN group, p,0.05; {p,0.05 from the AS-
UN group.
doi:10.1371/journal.pone.0110020.g009
Figure 10. Relationship between PGC1a - FoxO1 mRNA and protein expression in the plantaris muscle. There were significant negative
correlations between the PGC1a and FoxO mRNA/protein levels. For all correlations, individual data points from the AS-UN and AS-ET groups (n = 8
rats per group) were used.
doi:10.1371/journal.pone.0110020.g010
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remodeling was noted on an echocardiographic assessment,
although the animals did not show signs of HF. After 10 weeks
of aerobic ET, the AS-ET animals presented an improved in
structure and function in the systole and diastole compared with
AS-UN. In addition, ET prevented the deterioration of cardiac
structure and function in AS animals, when we compared the AS-
ET group and the 18-week AS rats. Our data support previous
findings that ET had a beneficial effect on the left ventricular
function of individuals with HF [41,42] and indicates that ET can
be an important clinical intervention for improving cardiac
structure and function during the transition from cardiac
dysfunction to HF.
Animal [10] and human [39] studies have demonstrated skeletal
muscle abnormalities in HF, including changes in morphology,
function, and depressed skeletal muscle aerobic capacity. In our
model of HF, we also observed changes in oxidative and glycolytic
skeletal muscle metabolic enzymes. The reduction of CS enzyme
activity in both the soleus and plantaris muscles in the AS-UN
group, suggests a decrease in aerobic metabolism. After 10 weeks
of aerobic ET, a significant attenuation in the decreasing CS
activity in AS-ET rats was evident. Although, our aerobic ET
protocol did not change this enzyme in the Sham-ET group,
probably due to the low training intensity used, CS was clearly
detected in the AS-ET animals. This prevention in the reduction
of CS activity in the AS-ET group may participate in de novo
ATP synthesis during ET in HF rats; therefore, the higher citrate
synthase activity in AS-ET rats than in AS-UN rats suggests
aerobic metabolism improvements. Furthermore, we observed an
increase in LDH enzyme in the AS-UN group, indicating higher
anaerobic metabolic activity in the skeletal muscle, which was
attenuated by ET. The changes in LDH activity were more
evident in the plantaris muscles of the AS-UN group, most likely
because this muscle has a higher frequency of Type II fibers
(glycolytic) than the soleus muscle. The increased percentage of
Type I fibers (oxidative metabolism) in the soleus and Type IIA
fibers (more oxidative compared with the IID and IIB fiber types)
in the plantaris muscle in the AS-ET group was further evidence
that ET attenuated the decrease in aerobic metabolism in these
muscles, because studies have shown that ET promotes a fiber type
transition and a myosin heavy chain content shift from a fast-to-
slow twitch [43,44]. Our findings regarding the fiber-type
transition during HF corroborate a report by Moreira et al. [45]
that moderate aerobic training increased the number of slow-
twitch fibers in the soleus and plantaris muscles. Thus, our data
strongly suggest that aerobic ET prevented the modulation of the
fiber type toward the more glycolytic metabolic pattern.
There is a striking association between skeletal muscle atrophy
and chronic HF [46]. Decreased muscle fiber CSA is a major
aggravator in HF syndrome and has been observed in experi-
mental HF studies [8,47,48]. However, the atrophy is dependent
on the model used and the type of muscle examined. Oxidative
muscles (e.g., the soleus) are more susceptible to damage caused by
inactivity or unloading, whereas glycolytic muscles (e.g., the
plantaris) tend to be more affected in diseased conditions [49,50].
Therefore, we decided to evaluate both the soleus and plantaris
muscles because of their contrasting metabolic properties. Soleus
atrophy in the AS-UN rats was correlated with a reduced CSA of
Type I and Type IIA muscle fibers. These findings are consistent
with a previous study by Moreira et al. [45], who also observed a
decrease in both fiber types (I and IIA) in the soleus muscle.
Moreover, in the plantaris muscle Moreira et al. [45] observed
atrophy only in the glycolytic-type fibers, similarly to our results,
which the plantaris muscle presented only IID and IIB glycolytic
fiber-type atrophy in the AS-UN rats. This result suggests that only
the glycolytic fiber types were more damaged under HF conditions
and might exhibit a greater loss of blood perfusion, and increased
damage from reactive oxygen species and local inflammation,
compared with oxidative fiber types [34,39,51].
Abnormalities in HF affect various endocrine systems leading to
an imbalance of catabolic and anabolic function. Skeletal muscle
atrophy during HF may be induced by the activation of local and
systemic markers of inflammation, most notably inflammatory
cytokine tumor necrosis factor (TNF-a), a proinflammatory
secreted cytokine that was originally called ‘‘cachectin’’ [52]. In
this study, similar to others [53,54], a significant increase in TNF-
a level were observed in the serum and in the tissue in our AS-UN
animals, while in the AS-ET animals, exercise attenuated the
expression of this cytokine. An anti-inflammatory effect of physical
exercise was recently proposed [55]; this effect may be mediated
not only by a reduction in visceral fat mass, with a subsequent
decrease in the production and release of proinflammatory
cytokines such as IL-6 and TNF-a, but also by the induction of
an anti-inflammatory environment with each bout of exercise [55].
Thus, our ET program in AS rats may have increased anti-
inflammatory cytokines in skeletal muscle, indicating a potential
mechanism for the anti-inflammatory effects of aerobic exercise in
cardiovascular disease.
Since TNF-a exhibit catabolic effects in various tissues [56], the
increased muscular expression of proinflammatory cytokine might
further contribute to the local catabolic state with progressive
atrophic alterations of the skeletal muscle in HF. The effects of
TNF-a on HF-related muscle myopathy are mediated through the
activation of a family of transcription factors known as nuclear
factor kappa B (NFkB), which regulate ubiquitin-dependent
proteosomal system activity (PDU) [57]. NFkB (p50/p65) activa-
tion leads to increased expression of the atrogenes MuRF1 and
MAFbx [57], which results in sarcomeric protein proteolysis,
promoting muscle atrophy. In our study, although there were
slight variations in the gene and/or protein expression levels of
NFkB, MuRF1, and MAFbx, the increased levels of these
catabolic components in the AS-UN group may be at least
partially responsible for the atrophy of the plantaris and soleus
muscles. Indeed, we previously demonstrated marked muscle
atrophy and a reciprocal increase in the components of the
ubiquitin-proteasome system (e.g., MuRF1 and MAFbx) in rats in
which HF was induced by monocrotaline [58]. These results
indicate the possible involvement of these atrogenes in the HF-
induced muscle atrophy process. Although several studies have
investigated the muscle atrophy that occurs during HF [40,45,58],
the effects of ET on the atrogene components have not been
completely defined. The present finding that aerobic ET
performed during the transition from cardiac dysfunction to HF
prevents the overactivation of some proteasomal components is
similar to that of Gielen et al. [59] that observed a attenuation of
MuRF1 by exercise training and Campos et al. [6], who also
observed a reduction of ubiquitin-proteasome system activation in
response to ET. Campos et al. [6] also indicated that the possible
attenuation of the ubiquitin-proteasome system by ET may be due
to improvements in the redox balance driven by the increase in
antioxidant enzymes and reduced levels of inflammatory cyto-
kines, corroborating our finding of a decrease in TNF-a levels
[4,6,54].
The transforming growth factor-b-related protein myostatin, a
key regulator of muscle growth, has been considered an important
mediator of cardiac-induced skeletal muscle wasting and cachexia
in animal studies [5,60]. However, the effects of ET on myostatin
expression in skeletal muscle remain inconclusive. Studies using
swimming endurance training have shown a reduction in the
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myostatin mRNA content in skeletal muscle [61,62]. Lenk et al.
[17] observed an increase in myostatin levels in the myocardium
and the gastrocnemius muscle in a rat model of ischemic
cardiomyopathy, and ET on a treadmill led to a significant
reduction in myostatin protein expression in the skeletal muscle
and myocardium of HF animals. Our results support these
findings; we observed a significant increase in myostatin expression
in the soleus and plantaris muscles in the AS-UN group and
aerobic ET prevented the increase in myostatin expression in the
AS-ET group in both muscles evaluated. Similar to Lenk et al.
[17], we also demonstrated that aerobic ET decreased the
expression of TNF-a. The significant reduction in myostatin levels
in the soleus and plantaris muscles after ET could be linked to the
reduction in the levels of the TNF-a; however, further experiments
investigating TNF-a levels and myostatin should be performed to
confirm the findings of the present study.
In chronic HF, alterations in multiple anabolic and catabolic
systems result in progressive catabolism, which leads to cardiac
cachexia in advanced stages of the disease [3]. As a key regulator
of normal muscle growth and hypertrophy, the role of the IGF-I/
AKT/mTOR signaling pathway has recently received increased
attention as a potential means of suppressing protein breakdown
while promoting muscle growth [9]. In patients with chronic HF
[7,37] and in animal models of chronic left-ventricular dysfunction
[10,63], reduced skeletal muscle expression of IGF-I is associated
with muscle atrophy. In addition, in advanced stages of HF have
been described low serum levels of IGF-I due to a growth
hormone resistance and a loss of lean muscle mass [3]. In the
present study, we observed low serum levels of IGF-I in AS-UN
rats compared to Sham-UN, without difference in AS-ET vs.
Sham-ET animals. In contrast, the tissue concentration of IGF-I
was similar among the groups, indicating that AS-induced HF did
not downregulate the IGF-I/AKT/mTOR pathway locally, and
suggesting that the although aerobic ET counteracted muscle
catabolism, aerobic ET did not enhance the muscle anabolic state.
Although disease progression from mild-moderate to severe HF is
likely multifactorial and is poorly understood, the available data
suggest that GH/IGF-I may be implicated in this pathology. A
possible explanation for these findings was suggested by Arcopinto
et al. [64], who stated that during the gradual development of HF
the IGF-I values are normal or slightly elevated in the beginning;
in the intermediate stage, IGF-I levels tend to decrease or remain
unaltered; and in advanced stages, IGF-I reduces and a markedly
increase in GH circulating levels occur. Furthermore, the changes
in skeletal muscle hypertrophy and atrophy turnover do not always
proceed according to the balance between protein breakdown and
protein synthesis [65]. Analyses of rat muscle growth by Li et al.
[66] demonstrated that starvation causes decreased protein
synthesis and increased protein degradation in both fast and slow
rat muscles. However, in a model of muscle denervation, the
authors observed an increase in protein degradation and an
increase rather than decrease in protein synthesis [67]. Taken
together, it is possible that in our experiment, the stage of HF
greatly influenced the catabolic components without any change in
the anabolic pathway and that the prevention of skeletal muscle
atrophy by ET occurred independent of protein synthesis.
The members of the forkhead box O (FoxO) family are
transcription factors responsible for the cross-talk between protein
degradation and protein synthesis [9]. Similar to Reed et al. [68],
who demonstrated that FoxO transcriptional activity is increased
in skeletal muscles under 2 cachectic conditions, we also observed
that HF-induced muscle atrophy is associated with an increase in
the expression of FoxO in both muscles studied. By contrast,
aerobic ET attenuated this change in FoxO expression; specif-
ically, the effects of aerobic ET in phosphorylate FoxO1,
contributing, at least in part, to the prevention of skeletal muscle
atrophy. Here, we extend our findings to the preventive effect of
aerobic ET on FoxO inhibition. FoxO activity is modulated by
other intracellular signaling molecules, such as peroxisome
proliferator-activated receptor gamma coactivator 1 alpha
(PGC1a), a cofactor involved in mitochondrial biogenesis, fiber-
type switching, and angiogenesis [69,70]. Low levels of PGC1a
have been reported to contribute to muscle wasting during chronic
HF [71]. We observed a decrease in the PGC1a levels only in the
plantaris muscle, although HF-induced atrophy was observed in
the soleus and plantaris muscles of the AS-UN animals.
Considering that glycolytic muscles are more vulnerable to
catabolic muscle wasting than are oxidative muscles [51,72] this
result demonstrates the distinct responses to HF stimuli in the
soleus and plantaris muscles, which in this case might be explained
by 2 main factors. The first is a decrease in blood supply, which
was likely more pronounced in the plantaris muscle than in the
soleus muscle. This difference could occur because the plantaris
muscle contains glycolytic fiber types, which receive less blood
and, consequently, reduced antioxidant defense [71]. The second
factor could be related to fiber-type modulation. The decrease in
the percentage of type IIA and increase in the IID fibers in the
plantaris muscle of AS-UN animals in our study, in association
with a decrease in the PGC1a content, supports previous findings
of Russell et al. [73], who showed that PGC-1 protein levels were
higher in the type IIA fibers, lower in the type I fibers, and lowest
in the type IID/X fibers in human skeletal muscle, thereby
suggesting the idea that the increase in the IID fiber types in
plantaris muscle in our experiment possibly induced the reduction
in the PGC1a content of AS-UN animals. By contrast, the absence
of changes in PGC1a levels in the soleus muscle could be related
to the Type I-to-IIA fiber conversion, which occurred within fiber
population in which PGC1a levels is already high [71,73]. In
addition, although our ET did not altered PGC1a levels in Sham-
ET group, moderate and intense aerobic ET is known to promote
an oxidative phenotype, stimulates PGC1a expression in skeletal
muscle [74], and by PGC1a overexpression prevents muscle
atrophy through the inhibition of the transcriptional activity of the
FoxO3, NFkB, and myostatin signaling pathways [9,75]. In the
current study, we observed that aerobic ET during the transition
from cardiac dysfunction to HF prevented the reduction in
PGC1a expression levels in the plantaris muscle. Of particular
interest, the expression levels of PGC1a and FoxO1 in this muscle
were negatively correlated (mRNA, r=20.69, p = 0.003; protein,
r=20.90, p,0.0001). Although these results do not demonstrate
a causal relationship between the anti-proteolytic component
PGC1a and the atrophic factor FoxO1 in AS-induced HF, they
confirm previous reports demonstrating a strong negative corre-
lation between these proteins and provide insights into the
functional role of PGC1a in the skeletal muscle in protection
against catabolic muscle wasting [14,71,75].
Although much has already been achieved, there is a great deal
more that we need to learn about ET applied during HF. Aerobic
exercise training is now an integral part of the recommended
treatment for stable New York Heart Association (NYHA) class I–
III HF patients [76]. Nevertheless, the understanding of the
molecular differences between beneficial vs. ‘maladaptive’ eccen-
tric cardiac growth will instruct potential future therapy. Also, the
precise definition of the molecular and cellular mechanisms
mediating the beneficial effects of ET during HF should be
elucidated to devise optimal treatment strategies that could in
theory beneficially impact cardiovascular diseases and HF.
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Limitations
Although the ascending AS is one of the more widely used
surgical methods to induce pressure overload in rats [22,47,77,78]
a limitation of this model is the evaluation of the grade of AS that
could be done by the analyze of the aorta flow velocity. As this
measurement is not reproducible technically in supravalvar AS in
rats, this issue can be partially solved by using the left ventricular
systolic pressure data [79] or by echocardiography parameters
[18], as we used in the present study.
The beneficial effects of aerobic ET protocol attenuating the
progression of the disease were evidenced in cardiac structure and
function parameters. However, we cannot conclude whether the
aerobic ET affected the skeletal muscles directly, or indirectly
preventing the deterioration from cardiac dysfunction to HF. In
addition, although we measured the degree of exercise tolerance
and performance, we did not make a direct assessment of skeletal
muscle force.
Finally, we used NFkB (p65) from nuclear and cytosolic fraction
for assessment of ubiquitin proteosomal system activity (PDU).
This protein does not allow us to verify the correct activity of the
NFkB, but taken together with others downstream protein
expression, this assay provides an important indicator of the
PDU involvement in skeletal muscle during the transition from
cardiac dysfunction to HF.
Conclusions
Collectively, our data provide evidence that aerobic ET
performed during the transition from cardiac dysfunction to HF
has beneficial effects on cardiac structure and function. Our results
also show that muscle atrophy observed in HF due to an increase
in catabolic pathways, was prevented by aerobic ET not via an
increase in anabolic factors but by counteracting the catabolic
activity, presumably by PGC1a expression.
Acknowledgments
We thank Dr. Frank Naya and his students Nelsa L. Estrella, Jose
Medrano, Amanda Rice, and Cody Desjardins for valuable discussions.
Author Contributions
Conceived and designed the experiments: RWAS ACC MDPS. Performed
the experiments: RWAS WPP LCS PATS DHSC AAHF KO. Analyzed
the data: RWAS WPP LCS PATS ACC AAHF KO. Contributed to the
writing of the manuscript: RWAS AFA IJVJ RFC MDPS.
References
1. Feldman AM, Weinberg EO, Ray PE, Lorell BH (1993) Selective changes in
cardiac gene expression during compensated hypertrophy and the transition to
cardiac decompensation in rats with chronic aortic banding. Circ Res 73: 184–
192.
2. Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, et al. (2008) Cachexia: a
new definition. Clin Nutr 27: 793–799.
3. Hambrecht R, Schulze PC, Gielen S, Linke A, Möbius-Winkler S, et al. (2002)
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27. De Sousa E, Lechêne P, Fortin D, N’Guessan B, Belmadani S, et al. (2002)
Cardiac and skeletal muscle energy metabolism in heart failure: beneficial effects
of voluntary activity. Cardiovasc Res 56: 260–268.
28. Siu PM, Donley DA, Bryner RW, Alway SE (2004) Myogenin and oxidative
enzyme gene expression levels are elevated in rat soleus muscles after endurance
training. J Appl Physiol 97: 277–285.
29. Picard MH, Adams D, Bierig SM, Dent JM, Douglas PS, et al. (2011) American
Society of Echocardiography recommendations for quality echocardiography
laboratory operations. J Am Soc Echocardiogr 24: 1–10.
30. Brooke MH, Kaiser KK (1970) Muscle fiber types: how many and what kind?
Arch Neurol 23: 369–379.
31. De Souza RWA, Aguiar AF, Carani FR, Campos GER, Padovani CR, et al.
(2011) High-intensity resistance training with insufficient recovery time between
bouts induce atrophy and alterations in Myosin heavy chain content in rat
skeletal muscle. Anat Rec (Hoboken) 294: 1393–1400.
32. Bass A, Brdiczka D, Eyer P, Hofer S, Pette D (1969) Metabolic differentiation of
distinct muscle types at the level of enzymatic organization. Eur J Biochem 10:
198–206.
Exercise Training Prevents Muscle Atrophy during Heart Failure
PLOS ONE | www.plosone.org 14 October 2014 | Volume 9 | Issue 10 | e110020
33. Wilkinson JH (1965) Introducción al diagnostic enzimático. 3a ed. Ediciones
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